Targeting OGG1 in Idiopathic Pulmonary Fibrosis

Introduction

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease with no curative therapies. Approved therapies for IPF have a high rate of discontinuation among patients due to adverse side effects and present a high unmet need for effective therapies.

OXC-201 Overview

Oxcia’s OXC-201 is a ground-breaking novel approach for the treatment of IPF, based on completely new biology. OXC-201 targets profibrotic and proinflammatory cascades at an early stage on a transcriptional level and is expected to efficiently prevent lung damage, creating a window for restorative processes to repair scar tissue.

Efficacy and Safety

OXC-201 has demonstrated significant efficacy in halting disease progression and improved safety and tolerability in preclinical IPF models.

TOPFIBRO Project Objectives

In the TOPFIBRO project, we will:

1. Obtain further proof of concept of OXC-201’s efficacy in improving lung function in vivo and confirm antifibrotic efficacy in patient-derived ex vivo models compared to the current standard of care.
2. Take OXC-201 through preclinical safety assessment studies.
3. Fulfill regulatory demands, preparation of IMPD, CTA, and ethical applications in order to initiate first-in-human studies.
4. Perform first-in-human clinical studies to determine the safety profile in healthy volunteers.
5. Develop a strong business plan with regulatory, financial, and clinical roadmaps to improve investor readiness.

Conclusion

These steps will allow us to further develop OXC-201 with the end goal of bringing it to market via a licensing deal with a large pharmaceutical company. OXC-201 has the potential to fill a large unmet need of the IPF patient community and present the first potentially curative therapy.